Brazil's health regulator Anvisa approved the registration of the Fluprevli trivalent influenza vaccine on Monday [2].
The authorization expands the available options for preventing the flu within the country, providing a new tool for public health officials to combat seasonal outbreaks. By targeting a wider age range, the vaccine aims to reduce the burden of respiratory illness across diverse population groups.
The vaccine is designed to protect against three strains of the virus, specifically influenza A and B [1]. The regulator said the immunization is indicated for adults and children starting at six months of age [1].
Anvisa published the decision in the Diário Oficial da União on July 13 [3]. This official registration allows the vaccine to be distributed and administered within the Brazilian healthcare system, though specific rollout dates for the general public were not detailed in the announcement.
The move comes as part of a broader effort to increase vaccine coverage and provide more specialized protection against circulating flu strains. Because the vaccine is trivalent, it offers a specific combination of antigens to trigger an immune response against the identified strains [1].
Public health officials said early immunization is important, particularly for infants and the elderly who are more susceptible to severe complications from the flu. The inclusion of children as young as six months ensures that a significant portion of the vulnerable population can be protected earlier in their development [1].
“The vaccine is trivalent, protecting against three strains of influenza A and B.”
The approval of Fluprevli represents a strategic expansion of Brazil's preventative healthcare toolkit. By lowering the age of eligibility to six months and utilizing a trivalent formula, the health authority is prioritizing the protection of high-risk pediatric populations and diversifying the types of influenza strains the population can resist, which may reduce hospitalization rates during peak flu seasons.
